uniQure NV
Fermé
49.16 11.52
Résumé
Variation du prix de l'action
24h
Min
44.17
Max
49.51
Revenu | -16M -54M |
|---|---|
Ventes | -2M 3.6M |
BPA | -0.73 |
Marge bénéficiaire | -1,502.948 |
Employés | 221 |
EBITDA | 13M -36M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +33.66% upside |
Prochains Résultats | 28 juil. 2026 |
|---|
Capitalisation Boursière | 454M 1.8B |
|---|---|
Ouverture précédente | 37.64 |
Clôture précédente | 49.16 |
uniQure NV Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
